Spyre says Phase 2 SKYLINE Part A met primary endpoint

Spyre said SPY003 met the primary endpoint in Phase 2 SKYLINE Part A, with a 10.0-point RHI reduction at Week 12 and supportive remission and endoscopic improvements. Part B is enrolling, with topline in 2027.